Abstract: The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention.
Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.
Type:
Grant
Filed:
August 29, 2013
Date of Patent:
February 14, 2017
Assignee:
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Inventors:
Susan P. James, Min Zhang, Guy Beauregard
Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
Type:
Grant
Filed:
September 5, 2013
Date of Patent:
February 7, 2017
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Sean Morrison, Elena Piskounova, Ugur Eskiocak
Abstract: Disclosed is a use of albiflorin or a metabolite thereof in preparation of antianxiety and sleep disorder improving drugs or health-care food. Tests prove that albiflorin has significant antianxiety effects and sleep disorder improving effects achieved by prolonging SWS and low the toxic side effects, thus being a safety monomer compound capable of effectively treating anxiety and sleep disorder.
Abstract: The invention relates to a method for enhancing a surfactant, in particular a pulmonary surfactant, as well as a method for producing a surfactant enhancement agent, in particular a pulmonary surfactant enhancement agent. The invention also relates to a surfactant enhancement agent and a use of an enhancement agent for enhancing a surfactant, in particular, a pulmonary surfactant. Further, the invention relates to a method of mitigating oxidative damage to pulmonary surfactant by adding a cholesterol-sequestrating agent such as cyclodextrin. Finally, a method is provided for treating a patient having surfactant dysfunction due to oxidative damage to pulmonary surfactant by administering a surfactant-protective amount of a cholesterol-sequestrating agent to protect the surfactant from the negative effects of oxidative degradation.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
January 17, 2017
Assignee:
SolAero Med Inc.
Inventors:
Matthias W. Amrein, Lasantha C. Gunasekara, Ryan Pratt
Abstract: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
Abstract: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization.
Type:
Grant
Filed:
August 7, 2013
Date of Patent:
January 10, 2017
Assignee:
WIsconsin Alumni Research Foundation
Inventors:
Samuel Helmer Gellman, Pil Seok Chae, Brian Kobilka, Soren Rasumssen
Abstract: The present disclosure provides, inter alia, a method of producing an outer layer material for forming into a structure and that comprises an entanglement having a hydrophobic polymer host and a hydrophilic guest, including in one embodiment the steps of: intermingling cloaked hydrophilic guest complexes with the hydrophobic host; crosslinking molecules of the guest with the guest; and performing a hydrolysis reaction.
Type:
Grant
Filed:
August 29, 2013
Date of Patent:
January 3, 2017
Assignee:
Colorado State University Research Foundation
Inventors:
Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski
Abstract: Compositions comprising LSF compositions and treatment regiments comprising administration of LSF containing compositions are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided.
Abstract: The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are —OSO3? or hydroxyl groups, R2 is an —O-alkyl group or a monosaccharide having Formula (II), R3 is a disaccharide having Formula (III), R5 is a disaccharide having Formula (IV), R7 is a hydroxyl group or a disaccharide having Formula (VI), and R9 is a hydroxyl or —O-alkyl group or a disaccharide having Formula (VII), where R10— is an —O-alkyl group. The invention further relates to the preparation of said oligosaccharides and to the therapeutic use thereof.
Type:
Grant
Filed:
February 9, 2012
Date of Patent:
December 27, 2016
Assignee:
SANOFI
Inventors:
Philippe Duchaussoy, Pierre Fons, Alexandre Froidbise
Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
Abstract: Described herein are phenolic compositions derived from apple skins. In particular, described herein are flavonoid-rich fractions derived from apple skin extract. The compositions are useful in the prevention and treatment of conditions associated with oxidative stress and/or inflammation, including certain neurodegenerative diseases. Methods of producing the compositions are also described.
Type:
Grant
Filed:
June 24, 2015
Date of Patent:
December 6, 2016
Assignee:
DALHOUSIE UNIVERSITY
Inventors:
Handunkutti Pathirannehalage Vasantha Rupasinghe, George S. Robertson
Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
Type:
Grant
Filed:
August 5, 2011
Date of Patent:
November 29, 2016
Assignee:
Seattle Genetics, Inc.
Inventors:
Peter Senter, Stephen Alley, Dennis Benjamin
Abstract: This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Abstract: The current invention provides methods (e.g., large-scale processes) for the production of nucleotide sugars, which are modified with a polymeric modifying group, such as poly(alkylene oxide) moieties (e.g., poly(ethylene glycol) or poly(propylene glycol)) moieties. A typical process of the invention includes anion exchange chromatography followed by an ultrafiltration procedure, such as tangential flow filtration. The process of the invention provides modified nucleotide sugars in unexpectedly high purity and high overall yields.
Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
Type:
Grant
Filed:
October 26, 2012
Date of Patent:
November 15, 2016
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Weihong Zheng, Minkui Luo, Glorymar del Valle Ibanez Sanchez
Abstract: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.
Abstract: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Abstract: The invention relates to a method for preparing a refined extract of Centella asiatica comprising a mixture of madecassoside and terminoloside. The method comprises: passage over adsorbent resin; elution with an eluent comprising at least 30 wt. % of an alcoholic solvent; and a recrystallization step using a mixture of solvents, comprising water and an alcoholic solvent.
Abstract: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.